AU Patent

AU2018347361A1 — Treatment of focal segmental glomerulosclerosis with CCR2 antagonists

Assigned to Chemocentryx Inc · Expires 2020-04-30 · 6y expired

What this patent protects

Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiment…

USPTO Abstract

Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018347361A1
Jurisdiction
AU
Classification
—
Expires
2020-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Chemocentryx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.